Report cover image

Hidradenitis Suppurativa Market - 2022-

Publisher DataM Intelligence 4Market Research LLP
Published Oct 14, 2025
Length 200 Pages
SKU # DTAM21125930

Description

Hidradenitis Suppurativa Market Overview:
The Hidradenitis Suppurativa Market was valued at USD 725.6 million in 2022 and is anticipated to reach by , at a CAGR of 0.048 from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Hidradenitis Suppurativa Market.

This report delivers a comprehensive overview of the Hidradenitis Suppurativa Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Hidradenitis Suppurativa Market. The Hidradenitis Suppurativa Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2022–.

Hidradenitis Suppurativa Market Scope:
By Clinical Stage
• Hurley Stage 1
• Hurley Stage 2
• Hurley Stage 3

By Skin Condition
• Folliculitis
• Pimples
• Boils
• Deep-Acne
• Others

By Treatment Type
• Surgery
• Medications
• Photodynamic Therapy (PDT)
• Laser Treatment
• Others

By Route of Administration
• Oral
• Parenteral
• Others

By End-user
• Hospitals
• Specialty Clinics
• Homecare
• Others

By Distribution Channel
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Key Players
• Pfizer Inc.
• Eli Lilly and Company
• AbbVie Inc.
• UCB S.A.
• Incyte Corporation
• Novartis AG
• Boehringer Ingelheim
• Aclaris Therapeutics, Inc.
• InflaRx N.V.
• Moonlake Immunotherapeutics

Major Highlights
This report delivers a comprehensive overview of the Hidradenitis Suppurativa Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Hidradenitis Suppurativa Market. The Hidradenitis Suppurativa Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2022–.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
South America (Colombia, Brazil, Argentina, Rest of South America)
Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification
Increase Your Customer Base by 3X using our Partner Identification tool
Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?
• Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
• Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
• White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
• Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
• Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
• Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

200 Pages
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Clinical Stage
3.2. Snippet by Skin Condition
3.3. Snippet by Treatment Type
3.4. Snippet by Route of Administration
3.5. Snippet by Distribution Channel
3.6. Snippet by End-user
3.7. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Prevalence of hidradenitis suppurativa
4.1.2. Restraints
4.1.2.1. Side effects associated with the treatment
4.1.3. Opportunity
4.1.3.1. Increasing research and development activities
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. Russia-Ukraine War Analysis
8. Artificial Intelligence Analysis
9. By Clinical Stage
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical Stage
9.1.2. Market Attractiveness Index, By Clinical Stage
9.2. Hurley Stage 1*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Hurley Stage 2
9.4. Hurley Stage 3
10. By Skin Condition
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Skin Condition
10.1.2. Market Attractiveness Index, By Skin Condition
10.2. Folliculitis*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Pimples
10.4. Boils
10.5. Deep-Acne
10.6. Others
11. By Treatment Type
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
11.1.2. Market Attractiveness Index, By Treatment Type
11.2. Surgery*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Medications
11.3.1. Biologics
11.3.2. Antibiotics
11.3.3. Hormonal Therapy
11.3.4. Immunosuppressive Drugs
11.3.5. Zinc Supplements
11.3.6. Retinoids
11.3.7. Pain Medication
11.4. Photodynamic Therapy (PDT)
11.5. Laser Treatment
11.6. Others
12. By Route of Administration
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.1.2. Market Attractiveness Index, By Route of Administration
12.2. Oral*
12.2.1. Introduction
12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.3. Parenteral
12.4. Others
13. By End-user
13.1. Introduction
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
13.1.2. Market Attractiveness Index, By End-user
13.2. Hospitals*
13.2.1. Introduction
13.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
13.3. Specialty Clinics
13.4. Homecare
13.5. Others
14. By Distribution Channel
14.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
14.2. Market Attractiveness Index, By Distribution Channel
14.3. Hospital Pharmacy*
14.3.1. Introduction
14.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
14.4. Retail Pharmacy
14.5. Online Pharmacy
14.6. Others
15. By Region
15.1. Introduction
15.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
15.1.2. Market Attractiveness Index, By Region
15.2. North America
15.2.1. Introduction
15.2.2. Key Region-Specific Dynamics
15.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical stage
15.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Skin Condition
15.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
15.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
15.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
15.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
15.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
15.2.9.1. The U.S.
15.2.9.2. Canada
15.2.9.3. Mexico
15.3. Europe
15.3.1. Introduction
15.3.2. Key Region-Specific Dynamics
15.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical stage
15.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Skin Condition
15.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
15.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
15.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
15.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
15.3.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
15.3.9.1. Germany
15.3.9.2. The U.K.
15.3.9.3. France
15.3.9.4. Italy
15.3.9.5. Spain
15.3.9.6. Rest of Europe
15.4. South America
15.4.1. Introduction
15.4.2. Key Region-Specific Dynamics
15.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical stage
15.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Skin Condition
15.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
15.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
15.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
15.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
15.4.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
15.4.9.1. Brazil
15.4.9.2. Argentina
15.4.9.3. Rest of South America
15.5. Asia-Pacific
15.5.1. Introduction
15.5.2. Key Region-Specific Dynamics
15.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical stage
15.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Skin Condition
15.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
15.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
15.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
15.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
15.5.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
15.5.9.1. China
15.5.9.2. India
15.5.9.3. Japan
15.5.9.4. Australia
15.5.9.5. Rest of Asia-Pacific
15.6. Middle East and Africa
15.6.1. Introduction
15.6.2. Key Region-Specific Dynamics
15.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical stage
15.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Skin Condition
15.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
15.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
15.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
15.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
16. Competitive Landscape
16.1. Competitive Scenario
16.2. Product Benchmarking
16.3. Company Share Analysis
16.4. Key Developments and Strategies
17. Company Profiles
17.1. Pfizer Inc.*
17.1.1. Company Overview
17.1.2. Product Portfolio and Description
17.1.3. Financial Overview
17.1.4. Key Developments
17.2. Eli Lilly and Company
17.3. AbbVie Inc.
17.4. UCB S.A.
17.5. Incyte Corporation
17.6. Novartis AG
17.7. Boehringer Ingelheim
17.8. Aclaris Therapeutics, Inc.
17.9. InflaRx N.V.
17.10. Moonlake Immunotherapeutics (*LIST NOT EXHAUSTIVE)
18. Appendix
18.1. About Us and Services
18.2. Contact Us

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us